Kornimate/medical-research-clean huggingface dataset:
preferences for services in a patient's first six months on antiretroviral therapy for hiv in zambia

Conditions: HIV

Summary: with the advent of universal eligibility for hiv treatment ("treat all") and same-day and community-based antiretroviral therapy (art) initiation, retention in care after a patient has started art remains the main challenge to achieving optimal outcomes in hiv treatment programs. consistently across both time and geography, the highest risk for loss from care is during a patient's first six months after art initiation, with about quarter of all patients not retained by the end of month 6. one of the reasons for the high attrition from care in this early retention period is that the model of care offered to most newly-initiating and re-initiating patients has barely evolved from its original outlines. patients in their first six months on art are generally not eligible for lower-intensity, patient-centered "differentiated service delivery" models that make remaining in care easier for experienced patients. instead, most early patients must still make multiple clinic visits that include clinical consultations with providers, and most can receive only 1-2 month supplies of medications at a time. this protocol is for the prefer-zambia study, an activity of the retain6 project. retain6 aims to develop new models of care for patients' first six months on art. prefer-zambia will collect data on patients' characteristics, clinical and non-clinical needs, and preferences for different types of services during their first six months after initiating art. the investigators will conduct an observational, prospective cohort survey of newly-initiated or re-initiated adult art patients at a selected set of 12 healthcare facilities in zambia. results are expected to inform the design of better models of service delivery for the early treatment period.


Eligibility criteria:
inclusion criteria: * living with hiv and on art for 0-6 six months at the study site * ≥ 18 years old (18 and older considered adult for research purposes in zambia) * presented at the study site for routine hiv-related care * provide written informed consent to participate. exclusion criteria: * unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant * not physically, mentally, or emotionally able to participate in the study, in the opinion of the investigators or study staff * unwilling to take the time required to complete the questionnaire on the day of consent

Keywords: hiv antiretroviral treatment differentiated service delivery retention in care zambia
clinical study on endoscopic management of gov1 esophagogastric varices

Conditions: Esophageal and Gastric Varices

Summary: the patients with gov1 esophagogastric varices will be treated with gastric variceal tissue gel injection, at the same time, the esophageal varices were treated with ligation, sclerotherapy, or no treatment. a new method for the treatment of esophageal varices will be proposed to improve the effective rate and reduce the recurrence rates and mortality, shorter hospital stays, and lower treatment costs, while further expanding hvpg testing to develop the best strategy for secondary prevention of endoscopic treatment in patients with gov1 type esophageal and gastric varices.

cirrhotic portal hypertension can cause esophageal and gastric varices, and esophageal and gastric varices bleeding (egvb) were associated with portal vein pressure. at present, the gold standard for detecting portal pressure in clinical practice is hepatic venous pressure gradient (hvpg). for sarin classification gov1 of esophagogastric varices are from a single origin, the left gastric vein. if the fundus varicose veins receive complete embolization treatment, the esophageal variceal blood flow should be completely blocked, and such patients do not need to perform esophageal surgery. however, this has not been reported in the literature. patients with esophageal and gastric varices identified by ct as gov1 will be enrolled, all of whom will receive hvpg detects. the patients were randomly divided into three groups. the patients in group a will receive endoscopic gel embolization for gastric varices and esophageal varices ligation treatment, group b patients will receive endoscopic gastric variceal tissue glue embolization and esophageal variceal sclerotherapy treatment, the patients in group c will receive endoscopic gelatinization of gastric fundus varices (esophageal varices were not treated). patients in the three groups were followed up with ctp and gastroscopy 1 month, 3 months, and 6 months after the initial treatment, and additional endoscopic treatment will be provided if necessary. if bleeding occurs again during this period, timely treatment (medication, endoscopy, intervention or surgery) is required according to the condition. a new method for the treatment of esophageal varices will be proposed to improve the effective rate and reduce the recurrence rates and mortality, shorter hospital stays, and lower treatment costs, while further expanding hvpg testing to develop the best strategy for secondary prevention of endoscopic treatment in patients with gov1 type esophageal and gastric varices.

Eligibility criteria:
inclusion criteria: * gov1 esophageal and gastric varices identified by ct; more than 18 years old; exclusion criteria: * complicated with liver cancer, severe cardiopulmonary insufficiency, stage iii and above hepatic encephalopathy, severe natural portal shunt formation, and previous treatment of portal hypertensive bleeding (including endoscopic, interventional, and surgical procedures).

Keywords: gov1 esophagogastric varices hvpg endoscopic treatment
endoscopic detection of dysplasia in crohn 's disease patient

Conditions: Crohn Disease Located in Jejunum or Ileum

Summary: patients with crohn's disease (cd) have an increased risk of small bowel adenocarcinoma (sba). long duration of cd is the main risk factor. sb dysplasia has been associated with sba in 20% of cases, always described in diseased sites. the progression to neoplasia and natural history remains unknown but progression of inflammation to dysplasia and then to adenocarcinoma is suspected. as for surveillance recommendations for colorectal carcinoma in long standing inflammatory colonic disease, endoscopic screening of sb could be proposed in cd patients with risk factors of sba. no study can be found in literature. the investigators propose a multicenter exploratory open study on prospective cohort of cd patients with high risk of dysplasia or cancer. the goal is evaluate the rate of dysplasia and adenocarcinoma detected by enteroscopy with biopsies in a high risk cd population


Eligibility criteria:
inclusion criteria: * more than 18-years-old * crohn disease on jejunum and/or ileum since at least 10 years * radiography done during last year exclusion criteria: * dysplasia previously detected * pregnancy

Keywords: crohn disease dysplasia adenocarcinoma endoscopy jejunum ileum
a biospecimen and clinical data study on patients for drug & biomarker discovery

Conditions: Alzheimer's Disease; Multiple Sclerosis; Parkinson's Disease; Huntington's Disease; Amyotrophic Lateral Sclerosis (ALS)

Summary: the purpose of this research project is to collect and store blood samples and clinical data. researchers can then use the stored samples in future studies. through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

blood samples are collected in the comfort and safety of your home by a certified medical professional. we have mobile phlebotomists located in major metropolitan areas around the nation for your convenience.

Eligibility criteria:
inclusion criteria: * males and females \>18 to 100 years old * a diagnosis of neurological condition * proof of diagnosis can be provided control group: healthy donors, males and females, 18 to 100 years of age exclusion criteria * receipt of blood products within 30 days of study enrollment * receipt of an investigational (unapproved) drug within 30 days of study enrollment

Keywords: alzheimer's disease multiple sclerosis parkinson's disease huntington's disease amyotrophic lateral sclerosis (als)
pretreatment quality of life as a predictor of distant metastasis-free survival and overall survival in patients with head and neck cancer

Conditions: Oncology

Summary: this study shed light on an under-researched area by examining the prognostic associations of pre-treatment qol with overall survival and distant metastasis free survival among patients with head and neck cancer who underwent free flap reconstruction. in addition, a validated instrument specific to head and neck cancer, i.e. the university of washington quality of life questionnaire (uw-qol) was adopted.

the importance of patient-related outcomes, especially quality of life (qol) has been recently emphasized in the field of oncology. in conjunction with traditional biomedical indicators, qol is recognized as a reliable parameter to reflect the health status of patients with malignancy. a growing body of evidence even points out that qol can produce prognostic information which goes beyond biomedical indicators. in particular, since qol may decline before any possible deterioration in health can be detected by existing biomedical measures, assessing pre-treatment qol possibly helps identify the patients who are susceptible to a higher risk of mortality after they receive cancer treatment, which may greatly facilitate the process of clinical decision making. despite the importance of pre-treatment qol, its prognostic associations with overall survival and distant metastasis free survival still remain relatively under-explored.

Eligibility criteria:
inclusion criteria: * patients with oral cavity, tongue, gingival, pharyngeal, laryngeal, or salivary gland cancer and cervical lymph node metastasis, and * received free flap reconstruction between november 2010 and june 2014 at a medical university hospital exclusion criteria: * patients with distant metastasis identified in their medical records, or * undergoing reconstruction other than anterolateral thigh, fibular bone and radial forearm flaps
helicobacter pylori eradication study

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study was to evaluate the efficacy and compliance of tailored therapy which using the polymerase chain reaction for point mutation of clarithromycin, compared to concomitant therapy, in patients without history of h. pylori eradication.

purpose of study\> 1. to evaluate the efficacy of tailored therapy compared to concomitant therapy. 2. difference in eradication rate according to the frequency of 23s ribosomal rna point mutation in clarithromycin. 3. to evaluate the compliance of tailored therapy compared to concomitant. 4. to analysis of factors which influence to the eradication rate. patients\> ; target disease * peptic ulcers(gastric ulcer, duodenal ulcer), * gastric maltoma, * endoscopic therapy state of early gastric cancer or gastric adenoma, * patients who require h. pylori testing by clinical judgment, such as chronic gastritis. method\> patients with h. pylori infection who have been screened for a 23s ribosomal rna point mutation (a2142g, a2143g point mutation) and randomized to a concomitant treatment group and a tailored treatment group. in concomitant treatment group, lansoprazole 30 mg, amoxicillin 1.0 g, metronidazole 500 mg and clarithromycin 500 mg were administered twice a day for 2 weeks, regardless of 23s ribosomal rna point mutation. in tailored treatment group, in the case of 23s ribosomal rna point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks. in tailored treatment group, in point mutation positive cases, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg for 2 weeks. for each treatment group, at least 4 weeks after completion of drug administration, confirm the sterilization and confirm the compliance and adverse effects of the drug.

Eligibility criteria:
inclusion criteria: * h. pylori infection diagnosed patient, between 18 years old and 80 years old * no history of h. pylori eradication therapy * no antibiotic use for more than 3 days within 1 month of treatment exclusion criteria: * history of taking antibiotics for more than 3 days in the last 1 month * history of subtotal or partial gastrectomy * patients with other systemic disorders such as severe liver function, kidney function, cardiopulmonary function abnormality * pregnant and lactating women * disagree with the survey or do not respond to the questionnaire * contraindications for each medications
telerehabilitation in the post-covid-19 patient (trials)

Conditions: Post-COVID-19 Syndrome

Summary: a major issue brought about by the current pandemic concerns the discontinuation of a large proportion of outpatient services provided locally, especially in the rehabilitation field. added to this situation is the ever-increasing demand for rehabilitation for post-coronavirus disease 19 (covid-19) patients. data show that respiratory and motor rehabilitation for people infected with covid-19 is necessary at all stages of the disease, even in the medium to long term after discharge from acute hospital care. also to be taken into account are the logistical difficulties imposed by restrictions on the movement of individuals within the territory for both patients and caregivers, which are amplified in remote or poorly served areas, such as many cross-border territories. in this context, telerehabilitation can provide solutions to assist healthcare facilities in managing the demand for rehabilitation in the territory using a 'digital' therapist. the main objective of this project is therefore to identify the appropriate technology to administer the rehabilitation programme to patients and apply to a group of post-covid-19 patients a customised respiratory and/or motor rehabilitation programme to be carried out directly at the patients' home after hospital discharge in order to evaluate its effects.


Eligibility criteria:
inclusion criteria: * adult patients admitted to a rehabilitation facility for functional recovery in disabling motor and/or respiratory outcomes of severe acute respiratory syndrome coronavirus 2 (sars-cov2) infection and residing in cross-border regions with a low density of rehabilitation offerings. exclusion criteria: * psychiatric disorders/cognitive impairments that do not allow proper use of tablets and breathing training devices.
the effect of desloratadine and levocetirizine on nasal obstruction (study p03609)

Conditions: Allergic Rhinitis

Summary: this was a study to measure the ability of desloratadine and levocetirizine to decrease nasal obstruction in subjects who had study-induced allergic rhinitis. study participants had allergic rhinitis symptoms induced in a vienna challenge chamber and then received desloratadine or levocetirizine for 8 days. after at least a 10 to 35-day washout period (time when no drug is given), subjects received the opposite treatment for 8 days. subjects had their total nasal symptom measured.on the 8th day of each treatment period.


Eligibility criteria:
inclusion criteria: * 18 to 45 years of age * were free of any clinically significant disease that would interfere with study evaluations. * demonstrated hypersensitivity to the grass allergen used in the chamber unless confirmed previously within 12 months. * hypersensitivity to the allergen was documented by a positive response to the skin prick test with a wheal diameter at least 3 mm larger than the diluent control and by a radioallergosorbent test (rast) class of \>=2 (rating scale 0 -6). * had a history of sar for at least 2 years, as diagnosed by the investigator, another physician, or subject-provided history. * reported having shown therapeutic efficacy with previous use of an antihistamine (without a decongestant). * at the screening allergen provocation, the subject had a nasal obstruction symptom severity score of at least moderate (\>=2) and a decrease from baseline in nasal airflow (ml/sec) measured by rhinomanometry of \>=30% within 2 hours of allergen exposure. also, the subject had a nasal obstruction symptom severity score of none or mild (\<=1) prior to exposure to allergen. exclusion criteria: * women who were pregnant or nursing. * had a body mass index (bmi) \>=30 kg/m\^2. * had asthma; were being treated with inhaled or oral corticosteroids, chromones, theophylline, leukotriene inhibitors, or short-acting inhaled β2-agonists (except during or immediately after the allergen exposures); and could not go through the washout periods and the entire study without needing these medications. * developed wheezing or dyspnea during the screening allergen exposure. * had a respiratory infection during the 4 weeks prior to pre-dose evaluations. * had any clinically significant deviation from normal in the physical examination that, in the investigator's judgment, could interfere with the study evaluation or affect subject safety. * had any history of or laboratory evidence of hepatic failure or renal failure with a glomerular filtration rate (gfr) known to be \<30 ml/min. * had a known potential for hypersensitivity, allergic, or idiosyncratic reaction to the study drug or excipients. * had nasal structural abnormalities, including large nasal polyps and marked septum deviation, that significantly interfered with nasal airflow.
clinical study to evaluate the maximum tolerated dose of bay1000394 given in a 3 days on / 4 days off schedule in subjects with advanced malignancies

Conditions: Neoplasms

Summary: clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of bay1000394 given in an intermittent 3 days on / 4 days off schedule to patients with advanced malignancies


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 - 1 * life expectancy of at least 12 weeks * subjects with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and / or if in the judgment of the investigator, experimental treatment is clinically and ethically acceptable * at least 1 tumor lesion measurable by computer tomography (ct) scan or magnetic resonance imaging (mri) according to recist 1.1 * adequate bone marrow, liver, and renal functions as assessed by the following laboratory requirements to be conducted within 14 days prior to the first dose of study drug exclusion criteria: * history of cardiac disease: congestive heart failure \> nyha class ii, unstable angina (anginal symptoms at rest), any episodes of angina or history of myocardial infarction, cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted), previous venous or arterial thrombotic events, pulmonary embolism * moderate or severe hepatic impairment, i.e. child-pugh class b or c(3) * history of human immunodeficiency virus (hiv) infection or chronic hepatitis b or c * active clinically serious infections of ctcae \> grade 2 (ctcae v4.02) * symptomatic metastatic brain or meningeal tumors unless the subject is \> 3 months from definitive therapy, has no evidence of tumor growth on an imaging study within 4 weeks prior to study entry, and is clinically stable with respect to the tumor at the time of study entry. subjects must not be on acute steroid therapy or taper off steroid therapy (chronic steroid therapy is acceptable provided that the dose is stable for 4 weeks prior to study entry and following screening ct / mri scan). subjects with neurological symptoms should undergo a ct / mri scan of the brain to exclude new or progressive brain metastases. spinal cord metastasis is acceptable * seizure disorder requiring therapy (such as steroids or anti-epileptics) * history of organ allograft * evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of ctcae \> grade 2 within 4 weeks prior to prior to the first dose of study drug

Keywords: phase i dose escalation kinase inhibitor cyclin-dependent kinases
colonization of bile ducts and infectious complications in cephalic duodenopancreatectomy

Conditions: Infection, Bacterial

Summary: cephalic duodenopancreatectomy is part of the curative treatment for pancreatic cancer of the head and peri-ampullary area. the mortality of the procedure is around 5%, with a morbidity ranging from 30 to 50%. infectious complications account for 35% of overall morbidity. one of the risk factors for postoperative complications is the existence of preoperative retentional jaundice, due to tumoral obstruction of the main bile duct in these cases, it is proposed to perform preoperative bile duct drainage, preferably by endoscopic stenting (ercp). however, several studies have shown these procedures to cause biliary contamination which could be responsible for an increase in post-operative morbidity such as infectious complications and increased length of stay in hospital.. thus, the biliary microbial flora is more often multi-microbial and may contain multidrug-resistant nosocomial germs, the study carried out by cortes et al., based on a control case study design, also showed that a correlation between biliary colonization and postoperative infectious complications existed in patients who benefited from a preoperative biliary drainage technique. in fact, the bacteria isolated during intraoperative bile sampling were similar, in 49% of cases, to those isolated during bacteriological samples collected postoperatively during infectious complications. the work carried out by krüger and al has shown that the spectrum of bacteria found in the preoperative bile samples from patients who have undergone bile duct dilation is potentially not covered by standard antibiotic therapy. the aim of this observational prospective study is to investigate this correlation between biliary colonization and postoperative infectious complications, to evaluate the morbidity and postoperative mortality of cephalic duodenopancreatectomies performed at the chru of nancy and to study a possible adaptation of perioperative antibiotic prophylaxis.


Eligibility criteria:
inclusion criteria: * age \> 18 years * patient operated for a planned cephalic duodenopancreatectomy * post-operative hospitalisation in icu * information leaflet given to the patient and the support person, with oral information, during the post-operative period exclusion criteria: * age \< 18 years * emergency duodenopancreatectomy (surgical indication period less than 48 hours)

Keywords: bile colonization cephalic duodenopancreatectomy